Gildeuretinol

Gildeuretinol
Clinical data
Other names	ALK-001, KL-49
Identifiers
	IUPAC name (2E,4E,6E,8E)-7-methyl-3-(trideuteriomethyl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol;
CAS Number	118139-35-8;
PubChem CID	169490774;
UNII	PSZ7W5NR24;
KEGG	D12713;
ChEMBL	ChEMBL5314606;
Chemical and physical data
Formula	C20H30D3O
Molar mass	292.500 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [2H]C([2H])([2H])/C(=C\CO)/C=C/C=C(\C)/C=C/C1=C(CCCC1(C)C)C;
	InChI InChI=InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+/i2D3; Key:FPIPGXGPPPQFEQ-QZNDTXPVSA-N;

Gildeuretinol is an investigational new drug being developed by Alkeus Pharmaceuticals for the treatment of retinal diseases, particularly Stargardt disease and geographic atrophy secondary to age-related macular degeneration (AMD). Stargardt disease is caused by a defect in the ABCA4 gene that clears toxic byproducts resulting from the dimerization of vitamin A. Gildeuretinol is a deuterated derivative of Vitamin A that is designed to reduce the dimerization of vitamin A without affecting the visual cycle.^[1]

Gildeuretinol has received breakthrough therapy and orphan drug designations from the U.S. Food and Drug Administration.^[2]

References

^ Zaydon YA, Tsang SH (July 2024). "The ABCs of Stargardt disease: the latest advances in precision medicine". Cell & Bioscience. 14 (1): 98. doi:10.1186/s13578-024-01272-y. PMC 11282698. PMID 39060921.
^ Fitch J (22 November 2024). "Gildeuretinol for Stargardt disease receives Rare Pediatric Disease, Fast Track Designations". Contemporary Pediatrics.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Zaydon_2024-1] Zaydon YA, Tsang SH (July 2024). "The ABCs of Stargardt disease: the latest advances in precision medicine". Cell & Bioscience. 14 (1): 98. doi:10.1186/s13578-024-01272-y. PMC 11282698. PMID 39060921.

[2] Fitch J (22 November 2024). "Gildeuretinol for Stargardt disease receives Rare Pediatric Disease, Fast Track Designations". Contemporary Pediatrics.

[1]

[2]